@diemhuyen711:

Diễm Huyền
Diễm Huyền
Open In TikTok:
Region: VN
Tuesday 01 September 2026 10:43:26 GMT
222
71
0
2

Music

Download

Comments

There are no more comments for this video.
To see more videos from user @diemhuyen711, please go to the Tikwm homepage.

Other Videos

Lp(a) Medicine Update!  Pelacarsen: - Antisense oligonucleotide targeting LPA mRNA - ↓ Lp(a) up to ~80% - Phase III Lp(a)HORIZON: 8,323 pts - Outcomes expected late 2026 - Possible approval: 2027 Olpasiran: - siRNA targeting LPA mRNA - ↓ Lp(a) ~95+ to at higher doses - Phase III OCEAN(a)-Outcomes: 7,297 pts - Expected completion: 2028 Lepodisiran:  - Long-acting siRNA - ↓ Lp(a) ~90 to 95% - Potentially only 1 or 2 injections/yr - Phase III ACCLAIM-Lp(a): ~17,300 patients - Expected completion: 2029 Muvalaplin:  - Oral small molecule preventing apo(a)-apoB100 assembly - ↓ Lp(a) ~70 to 85% - Phase III MOVE-Lp(a): ~10,450 patients - Expected completion: 2031 Zerlasiran:  - siRNA targeting LPA - ↓ Lp(a) ~80 to 97% - Phase II complete / Phase III-ready - Further development pending Safety: Reassuring so far, with mild injection site reactions the main issue with injectable therapies. Lp(a) lowering is also being studied as a potential treatment to slow calcific aortic stenosis, another disease strongly associated with elevated Lp(a). The first major answer should come from pelacarsen’s HORIZON trial in late 2026. If positive, we could see the first dedicated Lp(a)-lowering medication as early as 2027! - #doctor #medicine #health #wellness   #prevention  - Disclaimer: The contents of this video are for informational purposes only and are not intended to be medical advice, diagnosis, or treatment, nor to replace medical care. The information presented herein is accurate and conforms to the available scientific evidence to the best of the presenter/author’s knowledge as of the time of posting. Always seek the advice of your physician or other qualified health provider with any questions regarding any medical condition. Never disregard professional medical advice or delay seeking it because of information contained in this channel/post.
Lp(a) Medicine Update! Pelacarsen: - Antisense oligonucleotide targeting LPA mRNA - ↓ Lp(a) up to ~80% - Phase III Lp(a)HORIZON: 8,323 pts - Outcomes expected late 2026 - Possible approval: 2027 Olpasiran: - siRNA targeting LPA mRNA - ↓ Lp(a) ~95+ to at higher doses - Phase III OCEAN(a)-Outcomes: 7,297 pts - Expected completion: 2028 Lepodisiran: - Long-acting siRNA - ↓ Lp(a) ~90 to 95% - Potentially only 1 or 2 injections/yr - Phase III ACCLAIM-Lp(a): ~17,300 patients - Expected completion: 2029 Muvalaplin: - Oral small molecule preventing apo(a)-apoB100 assembly - ↓ Lp(a) ~70 to 85% - Phase III MOVE-Lp(a): ~10,450 patients - Expected completion: 2031 Zerlasiran: - siRNA targeting LPA - ↓ Lp(a) ~80 to 97% - Phase II complete / Phase III-ready - Further development pending Safety: Reassuring so far, with mild injection site reactions the main issue with injectable therapies. Lp(a) lowering is also being studied as a potential treatment to slow calcific aortic stenosis, another disease strongly associated with elevated Lp(a). The first major answer should come from pelacarsen’s HORIZON trial in late 2026. If positive, we could see the first dedicated Lp(a)-lowering medication as early as 2027! - #doctor #medicine #health #wellness #prevention - Disclaimer: The contents of this video are for informational purposes only and are not intended to be medical advice, diagnosis, or treatment, nor to replace medical care. The information presented herein is accurate and conforms to the available scientific evidence to the best of the presenter/author’s knowledge as of the time of posting. Always seek the advice of your physician or other qualified health provider with any questions regarding any medical condition. Never disregard professional medical advice or delay seeking it because of information contained in this channel/post.

About